People Could Identify When They Received THC, but No Other Drug Felt the Same
When trained to recognize the feeling of THC, participants could reliably identify it, but opioid, sedative, and stimulant drugs did not produce a THC-like experience.
Quick Facts
What This Study Found
Eight healthy moderate cannabis users learned to distinguish 25 mg oral THC from placebo under double-blind conditions, achieving at least 80% accuracy over four consecutive sessions.
Once trained, they were tested with multiple doses of THC, the sedative triazolam (a benzodiazepine), the opioid hydromorphone, and the stimulant methylphenidate (Ritalin).
All tested drugs produced measurable subjective effects on self-report questionnaires. However, only THC itself substituted for the training dose. Neither the opioid, nor the sedative, nor the stimulant was mistaken for THC.
This suggests the subjective experience of THC is distinct from the effects produced through opioid, GABA, and dopamine systems.
Key Numbers
8 subjects completed the study. Training dose: 25 mg oral THC. Discrimination criterion: 80%+ accuracy for 4 consecutive sessions. Only THC substituted for itself; triazolam, hydromorphone, and methylphenidate did not.
How They Did This
Double-blind, placebo-controlled drug discrimination study. Eight moderate cannabis users were trained to identify 25 mg oral THC. Once discrimination was acquired (80%+ accuracy for four sessions), multiple doses of THC, triazolam, hydromorphone, and methylphenidate were tested for substitution.
Why This Research Matters
Understanding whether THC shares subjective properties with other drug classes helps clarify its unique pharmacology and abuse potential. The finding that no tested drug mimicked THC suggests cannabinoid effects are pharmacologically distinct.
The Bigger Picture
Drug discrimination studies help map the subjective landscape of different drug classes. The unique discriminative properties of THC suggest that the cannabinoid system produces a distinct subjective experience not easily replicated by drugs acting on other neurotransmitter systems.
What This Study Doesn't Tell Us
Very small sample (8 participants). Only oral THC was tested, which has a different pharmacokinetic profile than smoked cannabis. The drugs tested represent only a few neurotransmitter systems; other mechanisms were not examined.
Questions This Raises
- ?What specific aspects of the THC experience make it distinguishable?
- ?Would synthetic cannabinoids substitute for THC in this paradigm?
- ?Could CBD modify the discriminative properties of THC?
Trust & Context
- Key Stat:
- Only THC substituted for THC; opioid, sedative, and stimulant drugs did not
- Evidence Grade:
- Small sample (n=8) in a controlled laboratory setting using established drug discrimination methodology.
- Study Age:
- Published in 2009. Drug discrimination methodology remains a standard tool for characterizing subjective drug effects.
- Original Title:
- Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.
- Published In:
- Psychopharmacology, 203(2), 241-50 (2009)
- Authors:
- Lile, Joshua A(5), Kelly, Thomas H(2), Pinsky, David J, Hays, Lon R
- Database ID:
- RTHC-00369
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
What does drug discrimination mean in research?
Drug discrimination is a method where participants learn to tell whether they received a specific drug or placebo. Once they can reliably tell the difference, researchers test whether other drugs feel similar. It reveals whether different substances share subjective properties.
Does this mean THC is completely unique?
Among the drugs tested (opioid, sedative, stimulant), none produced a THC-like experience. However, other cannabinoid receptor agonists (synthetic cannabinoids) would likely substitute for THC, as they act on the same receptor system.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- why-does-weed-make-you-laugh-thc-humor
- thc-and-adderall-stimulants-cannabis-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00369APA
Lile, Joshua A; Kelly, Thomas H; Pinsky, David J; Hays, Lon R. (2009). Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.. Psychopharmacology, 203(2), 241-50. https://doi.org/10.1007/s00213-008-1393-3
MLA
Lile, Joshua A, et al. "Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.." Psychopharmacology, 2009. https://doi.org/10.1007/s00213-008-1393-3
RethinkTHC
RethinkTHC Research Database. "Substitution profile of Delta9-tetrahydrocannabinol, triazol..." RTHC-00369. Retrieved from https://rethinkthc.com/research/lile-2009-substitution-profile-of-delta9tetrahydrocannabinol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.